Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 101 related to Waldmann: The multichain interleukin-2 receptor: a target for immunotherapy. (0.12 sec) 

The multichain interleukin-2 receptor: a target for immunotherapy


TA Waldmann, IH Pastan, OA Gansow, RP … - Annals of internal …, 1992 - Am Coll Physicians
Activation of resting T-lymphocytes induces synthesis of interleukin-2 (IL-2) and expression of
cell surface receptors for this lymphokine. In contrast to resting normal T-cells that do not express
high-affinity IL-2 receptors (IL-2R), abnormal T-cells of patients with leukemia-lymphoma, ...
Cited by 83 - Related articles - All 4 versions

[PDF] Radioimmunotherapy of human B-cell lymphoma with 90Y-conjugated antiidiotype …


BA Parker, AB Vassos, SE Halpern, RA Miller, H Hupf, … - Cancer Res, 1990 - AACR
(CANCER RESEARCH (SUPPL.) 50, 1022s-1028s. Februar) l. 1990] Radioimmunotherapy of
Human B-Cell Lymphoma with 90Y-conjugated ... Barbara A. Parker,2 Artemios B. Vassos, Samuel
E. Halpern, Richard A. Miller, Homer Hupf, Diane G. Amox, Joseph L. Simoni, Robin J. ...
Cited by 56 - Related articles - All 3 versions

A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 …

- ascopubs.org [PDF] 
DA Scheinberg, DJ Straus, SD Yeh, C Divgi, P … - Journal of Clinical …, 1990 - jco.ascopubs.org
H EMATOPOIETIC neoplasms have long been considered potential targets for mon- oclonal
antibody (mAb) therapy because of their accessibility to the blood, their well-defined cell surface
antigens, and their sensitivity to mAb- delivered radiation.' Early trials with unmodified ...
Cited by 68 - Related articles - All 6 versions

Internal radiation dosimetry for clinical testing of radiolabeled monoclonal …


DR Fisher, JS Durham, TE Hui, RL Hill - 1990 - osti.gov
Presented at the Third Conference on Radioimmunodetection and Radioimmunotherapy of Cancer
Princeton, New Jersey November 15-17, 1990 ... Work supported by the US Department of Energy
under Contract DE-ACO6-76RLO 1830 ... _$TR!_BI_IT!_fl_ OF TFII_ IIGP.IIMI:_T i: II_1 iMl' ...
Cited by 18 - Related articles - View as HTML

The interleukin-2 receptor: a target for monoclonal antibody treatment of human T- …

- hematologylibrary.org [PDF] 
TA Waldmann, JD White, CK Goldman, L Top … - …, 1993 - bloodjournal.hematologylibrary.org
. reserved Hematology; all rights Copyright 2007 by The American Society of Suite 200, Washington
DC 20036. semimonthly by the American Society of Hematology, 1900 M St, NW, Blood (print
ISSN 0006-4971, online ISSN 1528-0020), is published ... For personal use only. at ...
Cited by 134 - Related articles - BL Direct - All 5 versions

Biophysical characterization of a recombinant soluble interleukin 2 receptor (Tac)


RP Junghans, AL Stone, MS Lewis - Journal of Biological Chemistry, 1996 - ASBMB
The interleukin 2 receptor (IL2R) plays a prominent role in the biology of T cells, B cells, and
NK cells during activation. Of the three chains described, the α-chain of the receptor (Tac;
IL2Rα; CD25) is the most subject to regulation and is shed from the surface of activated ...
Cited by 19 - Related articles - BL Direct - All 4 versions

[PDF] Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1


GL DeNardo, SJ DeNardo, LF O'Grady, NB Levy, GP … - Cancer Res, 1990 - AACR
Eighteen patients with Stage 4 B-cell malignancies, which were pri marily of intermediate or high
grade and progressive despite multiple drug chemotherapy and external irradiation, were treated
with fraction ated doses of '" I-labeleil Lym-1. Lym-1 is an IgG2a monoclonal antibody that ...
Cited by 82 - Related articles - All 3 versions

Treatment of lymphoma with radiolabeled antibody: elimination of tumor cells …

- oxfordjournals.org [PDF] 
C Nourigat, CC Badger, ID … - JNCI Journal of the …, 1990 - jnci.oxfordjournals.org
We have previously shown that 131 I- labeled monoclonal antibodies against the Thyl.l differentiation
antigen can induce the regression of Thyl.l antigen-positive (Thyl.l+) AKR/J SL2 T cell lymphoma
nodules in AKR/Cum (Thyl.2 + ) mice. In this study, we ex- amined the ability of 131 ...
Cited by 46 - Related articles - All 5 versions

Administration of disulfide-stabilized Fv-immunotoxins B1 (dsFv)-PE38 and B3 ( …


I Benhar, Y Reiter, LH Pai, I Pastan - International Journal of …, 1995 - interscience.wiley.com
B1 (dsFv)-PE38 and B3(dsFv)-PE38 are recombinant immunotoxins in which the Fv fragments
of MAbs B1 and B3, respectively, are stabilized by an engineered interchain disulfide bond and
are fused at their C-termini to a modified Pseudomonas exotoxin from which the ...
Cited by 29 - Related articles - BL Direct - All 3 versions

Determinants of the antitumor effect of radiolabeled monoclonal antibodies

- aacrjournals.org [PDF] 
SJ Knox, R Levy, RA Miller, W Uhland, J Schiele, W … - Cancer Research, 1990 - AACR
ABSTRACT The murine B-cell lymphoma 38C13 model was used to study the radiobiological
effect of 13ll-monoclonal antibody (MAB) therapy com pared with dose equivalent external beam
irradiation. Continuous expo nentially decreasing low dose rate (LDR) -y-irradiation, and ...
Cited by 52 - Related articles - All 2 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google